Insilico and CMS Team Up Again as AI Drug Development Turns Toward CNS Diseases
From an anti-fibrotic drug entering late-stage clinical development to a new CNS collaboration, Insilico’s AI drug discovery narrative is being pulled back to a stricter question: can algorithms deliver drug candidates that experiments and clinical practice will recognize in the field of brain diseases, where penetration and validation are among the hardest challenges?